BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Alzheimer’s disease

  Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing

  With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval in the second half of 2025.

  January 2, 2025

   · 

  3 min read

   · 

  Nick Paul Taylor
• 

  Business

  Trials and Capital: Women’s Health and APAC’s Healthcare Revolution

  In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.

  January 2, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Gene therapy

  Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact

  Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.

  January 2, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Depression

  Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial

  In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.

  January 2, 2025

   · 

  2 min read

   · 

  Heather McKenzie
• 

  FDA

  2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US

  Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.

  January 2, 2025

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Career Advice

  Computational Biology, Data Science Hot Areas for Oncology R&D Hiring

  As market values increase for computational biology and data science, biopharma companies are looking to hire R&D professionals in those areas. A biotech talent acquisition expert shares his insights on these in-demand roles.

  January 2, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Antibody drug conjugate

  Roche Kicks Off 2025 Committing a Potential $1B for Another ADC From China

  Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal with Innovent for $1 billion in biobucks.

  January 2, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Job Trends

  7 Companies Hiring in California

  Job postings in California took a dip in December during the holiday period, but activity is expected to pick up in January.

  January 2, 2025

   · 

  1 min read

   · 

  Chantal Dresner
• Press Releases

  Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference

  January 2, 2025

   · 

  1 min read
• Press Releases

  HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

  January 2, 2025

   · 

  10 min read